Astellas licenses Claudin18.2 ADC from China’s Evopoint Biosciences

Astellas is the latest large pharmaceutical company to ink a deal with a Chinese biotech, paying $130 million upfront for a Claudin18.2-targeted antibody-drug conjugate from Evopoint Biosciences. The Suzhou-based biotech could receive another $70 million …